Kenvue loses bid for rehearing after Tylenol autism lawsuits revived

By Reuters News

By Diana Novak Jones

Oct 16 (Reuters) - A US appeals court said on Friday it won’t reconsider a ruling reviving hundreds of lawsuits against Tylenol maker Kenvue alleging the popular painkiller can cause autism.

  • In a brief order, the 2nd US Circuit Court of Appeals in Manhattan said it was rejecting a request from the company, which was spun off from Johnson & Johnson, to reconsider the three-judge panel’s ruling or to have the full court hear the case

  • In July, the panel revived about 500 lawsuits filed by parents over claims Tylenol use during pregnancy is linked to autism and attention deficit hyperactivity disorder (ADHD) in children

  • In that ruling, the court said a district court judge improperly excluded expert testimony from three doctors supporting the parents’ claims

  • Kenvue asked the court to reconsider the decision, saying district judges are the "true gatekeepers" who decide ⁠whether evidence is reliable enough to be admitted at trial

  • A spokesperson for Kenvue did not immediately respond to a request for comment

  • Friday’s ruling could pave the way for the company to appeal to the US Supreme Court

  • The issue drew greater attention after PresidentDonald Trump and top US health officials suggested a ​link to autism

  • There is no firm scientific evidence ​of a link between the drug and the conditions

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.